On the other hand, changes in TIL associated with superior anti-tumor efficacy for the combination STING-based immunotherapies in the B16 model were subtle and primarily linked to elevated frequencies of activated CD8+CD69+ T cells, with CD45neg tumor/stromal cells coordinately expressing higher levels of MHC-II expression. The gene discussed is CD8A; the disease is neoplasm.